Biomab Brilliant Limited entered into a definitive agreement to acquire remaining 25% stake in Biomab Holding Limited from Cipla Limited (NSEI:CIPLA) for $25.8 million on October 29, 2015. Biomab Brilliant will acquire 8.73 million shares of Biomab Holding Limited. The transaction is subject to conditions precedent and receipt of applicable regulatory and other approvals. Barclays PLC (LSE:BARC) acted as financial advisor for Cipla. Kelly Gregory, Emma C Davies, Campbell Izzard, Jay Liang, John Koshy and Peter Zhao of Clifford Chance acted as legal advisors to Cipla.

Biomab Brilliant Limited completed the acquisition of remaining 25% stake in Biomab Holding Limited from Cipla Limited (NSEI:CIPLA) on January 22, 2016.